CD4 and neoplasm: Our data is consistent with a model in which HIF-2α inhibition promotes phagocytosis, while dual ICB re-invigorates exhausted T cells, favoring the possibilities for TAMs to present or cross-present tumor-derived antigens to CD4+ and CD8+ T cells and promote local T-cell re-activation and tumor control [12, 57].